COMPASS THERAPEUTICS, INC. Proceeds from Issuance or Sale of Equity
COMPASS THERAPEUTICS, INC. (CMPX) reported Proceeds from Issuance or Sale of Equity of $568.00 million for the 99-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2026-06-30 was $0.00.
- COMPASS THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2025-09-30 was $138.00M.
- COMPASS THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2025-06-30 was $0.00.
- COMPASS THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2024-09-30 was $0.00.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 51 month | Proceeds from Issuance or Sale of Equity 51 month as first filed | Proceeds from Issuance or Sale of Equity 54 month | Proceeds from Issuance or Sale of Equity 54 month as first filed | Proceeds from Issuance or Sale of Equity 60 month | Proceeds from Issuance or Sale of Equity 72 month | Proceeds from Issuance or Sale of Equity 75 month | Proceeds from Issuance or Sale of Equity 78 month | Proceeds from Issuance or Sale of Equity 84 month | Proceeds from Issuance or Sale of Equity 87 month | Proceeds from Issuance or Sale of Equity 90 month | Proceeds from Issuance or Sale of Equity 96 month | Proceeds from Issuance or Sale of Equity 99 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 99 month − 10-Q 96 month · filed 2026-08-06 | $568.00M 10-Q · filed 2026-08-06 | |||||||||||||
| 2026-03-31 | $568.00M 10-Q · filed 2026-05-05 | ||||||||||||||
| 2025-09-30 | $138.00M derived: 10-Q 90 month − 10-Q 87 month · filed 2025-11-05 | $138.00M derived: sum of 2 quarters · filed 2025-11-05 | $568.00M 10-Q · filed 2025-11-05 | ||||||||||||
| 2025-06-30 | $0.00 derived: 10-Q 87 month − 10-Q 84 month · filed 2025-08-11 | $430.00M 10-Q · filed 2025-08-11 | |||||||||||||
| 2025-03-31 | $430.00M 10-Q · filed 2025-05-08 | ||||||||||||||
| 2024-09-30 | $0.00 derived: 10-Q 78 month − 10-Q 75 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $430.00M 10-Q · filed 2024-11-12 | ||||||||||||
| 2024-06-30 | $0.00 derived: 10-Q 75 month − 10-Q 72 month · filed 2024-08-12 | $430.00M 10-Q · filed 2024-08-12 | |||||||||||||
| 2024-03-31 | $430.00M 10-Q · filed 2024-05-13 | ||||||||||||||
| 2023-03-31 | $409.00M 10-Q · filed 2023-05-04 | ||||||||||||||
| 2022-09-30 | $0.00 derived: 10-Q 54 month − 10-Q 51 month · filed 2023-11-09 | $412.00M 10-Q · filed 2023-11-09 | $329.00M 10-Q · filed 2022-11-09 | ||||||||||||
| 2022-06-30 | $412.00M 10-Q · filed 2023-08-03 | $329.00M 10-Q · filed 2022-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |